What was studied?
A multicenter randomized, double-blind, placebo-controlled phase 2 study investigated oral glutathione in young children with cystic fibrosis and pancreatic insufficiency. The main endpoint was change in weight-for-age score over 24 weeks.
What did the researchers report?
The reported analysis found no significant group differences in the primary growth score, absolute weight or BMI changes. Other investigated clinical and inflammatory endpoints also did not show significant differences.
What are the limits?
The findings concern a specific pediatric disease population and oral formulation. They do not establish benefit in other populations, but they also should not be omitted in favor of favorable biomarker studies. This report is not guidance for children or evidence about other administration routes.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.